Outlook Therapeutics (OTLK) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.49, -2.36% vs the prior close of $0.50.
- Volume 3.09M shares, 0.3x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
OTLK dips 2.4% to $0.49. Closed at $0.49, -2.36% vs the prior close of $0.50. Day range $0.49–$0.53, opened at $0.52.
OTLK daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — OTLK dips 2.4% to $0.49
- Closed at $0.49, -2.36% vs the prior close of $0.50. Day range $0.49–$0.53, opened at $0.52.
- Volume was 3.09M shares, 0.3x its 50-day average of 11.75M — lighter than usual.
- Price is -27.3% vs its 50-day average ($0.67) and -27.2% vs its 200-day average ($0.67).
- 52-week range $0.16–$2.54; today's close sits at 14% of that range, 80.8% below the 52-week high.
Oct 15, 2026 — OTLK jumps 6.4% to $0.50
- Closed at $0.50, +6.38% vs the prior close of $0.47. Day range $0.44–$0.51, opened at $0.49.
- Volume was 5.33M shares, 0.5x its 50-day average of 11.75M — lighter than usual.
- Price is -26.6% vs its 50-day average ($0.68) and -26.2% vs its 200-day average ($0.68).
- 52-week range $0.16–$2.54; today's close sits at 14% of that range, 80.3% below the 52-week high.
Oct 14, 2026 — OTLK slides 16.7% to $0.47, a 3-month low, 3 down days in a row
- Closed at $0.47, -16.67% vs the prior close of $0.56. Day range $0.47–$0.56, opened at $0.56.
- Volume was 9.64M shares, 0.8x its 50-day average of 11.84M.
- Price is -32.1% vs its 50-day average ($0.69) and -31.4% vs its 200-day average ($0.68).
- 52-week range $0.16–$2.54; today's close sits at 13% of that range, 81.5% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — OTLK slides 3.6% to $0.56
- Closed at $0.56, -3.59% vs the prior close of $0.58. Day range $0.55–$0.58, opened at $0.58.
- Volume was 3.25M shares, 0.3x its 50-day average of 11.90M — lighter than usual.
- Price is -19.6% vs its 50-day average ($0.70) and -18.5% vs its 200-day average ($0.69).
- 52-week range $0.16–$2.54; today's close sits at 17% of that range, 77.8% below the 52-week high.
Oct 12, 2026 — OTLK dips 2.3% to $0.58
- Closed at $0.58, -2.34% vs the prior close of $0.60. Day range $0.57–$0.60, opened at $0.60.
- Volume was 2.31M shares, 0.2x its 50-day average of 12.02M — lighter than usual.
- Price is -17.4% vs its 50-day average ($0.71) and -16.2% vs its 200-day average ($0.70).
- 52-week range $0.16–$2.54; today's close sits at 18% of that range, 77.0% below the 52-week high.
Oct 9, 2026 — OTLK jumps 6.2% to $0.60
- Closed at $0.60, +6.21% vs the prior close of $0.56. Day range $0.56–$0.61, opened at $0.57.
- Volume was 3.68M shares, 0.3x its 50-day average of 12.14M — lighter than usual.
- Price is -16.4% vs its 50-day average ($0.72) and -15.0% vs its 200-day average ($0.70).
- 52-week range $0.16–$2.54; today's close sits at 18% of that range, 76.4% below the 52-week high.
Oct 8, 2026 — OTLK slides 4.4% to $0.56, a 3-month low
- Closed at $0.56, -4.41% vs the prior close of $0.59. Day range $0.55–$0.59, opened at $0.58.
- Volume was 4.00M shares, 0.3x its 50-day average of 12.63M — lighter than usual.
- Price is -22.2% vs its 50-day average ($0.73) and -20.6% vs its 200-day average ($0.71).
- 52-week range $0.16–$2.54; today's close sits at 17% of that range, 77.8% below the 52-week high.
Oct 7, 2026 — OTLK jumps 3.1% to $0.59
- Closed at $0.59, +3.15% vs the prior close of $0.57. Day range $0.58–$0.61, opened at $0.60.
- Volume was 4.23M shares, 0.3x its 50-day average of 13.25M — lighter than usual.
- Price is -19.6% vs its 50-day average ($0.73) and -17.8% vs its 200-day average ($0.72).
- 52-week range $0.16–$2.54; today's close sits at 18% of that range, 76.8% below the 52-week high.
Oct 6, 2026 — OTLK slides 4.0% to $0.57, a 3-month low
- Closed at $0.57, -4.03% vs the prior close of $0.60. Day range $0.57–$0.62, opened at $0.60.
- Volume was 3.16M shares, 0.2x its 50-day average of 13.99M — lighter than usual.
- Price is -22.7% vs its 50-day average ($0.74) and -21.1% vs its 200-day average ($0.73).
- 52-week range $0.16–$2.54; today's close sits at 17% of that range, 77.5% below the 52-week high.
Oct 5, 2026 — OTLK rises 0.5% to $0.60, 3 up days in a row
- Closed at $0.60, +0.51% vs the prior close of $0.59. Day range $0.58–$0.61, opened at $0.60.
- Volume was 4.69M shares, 0.3x its 50-day average of 15.05M — lighter than usual.
- Price is -20.5% vs its 50-day average ($0.75) and -18.8% vs its 200-day average ($0.73).
- 52-week range $0.16–$2.54; today's close sits at 18% of that range, 76.5% below the 52-week high.
- That makes 3 straight gains.
Oct 2, 2026 — OTLK jumps 3.1% to $0.59
- Closed at $0.59, +3.13% vs the prior close of $0.57. Day range $0.57–$0.61, opened at $0.59.
- Volume was 5.62M shares, 0.4x its 50-day average of 15.06M — lighter than usual.
- Price is -22.6% vs its 50-day average ($0.77) and -20.2% vs its 200-day average ($0.74).
- 52-week range $0.16–$2.54; today's close sits at 18% of that range, 76.6% below the 52-week high.
OTLK latest news & SEC filings
Every SEC filing by or about OTLK in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Sep 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 2, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 19, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 18, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$20.32M (prior year -$20.15M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.15 (prior year -$0.55) (loss narrowed vs Jun 30, 2025)
Aug 17, 2026 · Form NT 10-Q — Notice of late quarterly report
Notice of late quarterly report
Aug 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Jahr Robert Charles bought 151,515 shares on Aug 14, 2026
- Jahr Robert Charles bought 151,515 shares on Aug 14, 2026
- Jahr Robert Charles bought 151,515 shares on Aug 14, 2026
- Jahr Robert Charles bought 151,515 shares on Aug 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Sukhtian Ghiath M. bought 2,525,252 shares at $0.99 (≈$2.50M) on Aug 12, 2026
- Sukhtian Ghiath M. bought 2,525,252 shares at $0.99 (≈$2.50M) on Aug 12, 2026
- Gms Ventures & Investments bought 2,525,252 shares at $0.99 (≈$2.50M) on Aug 12, 2026
- Gms Ventures & Investments bought 2,525,252 shares at $0.99 (≈$2.50M) on Aug 12, 2026
- Sukhtian Ghiath M. bought 2,525,252 shares at $0.99 (≈$2.50M) on Aug 12, 2026
- Sukhtian Ghiath M. bought 2,525,252 shares at $0.99 (≈$2.50M) on Aug 12, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kenyon Lawrence A bought 101,010 shares on Aug 14, 2026
- Kenyon Lawrence A bought 101,010 shares on Aug 14, 2026
- Kenyon Lawrence A bought 101,010 shares on Aug 14, 2026
- Kenyon Lawrence A bought 101,010 shares on Aug 14, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form 424B5 — Prospectus supplement
Prospectus supplement — the company is selling securities off a shelf registration
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade OTLK
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: Aug 12, 2026, May 18, 2026, May 13, 2026. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.99% (largest 16.7%). That is a volatile stock.
- Liquidity: about 4.51M shares (≈$2.20M) trade per day on average.
- 52-week position: $0.49 vs a range of $0.16–$2.54 (14% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 25 open-market buys, 0 sales; latest: Lawrence A Kenyon bought 101,010 shares on Aug 14, 2026.
- Latest filings: 8-K Sep 30, 2026; 8-K Sep 18, 2026; 8-K Aug 27, 2026.
- Share count: 243.45M shares outstanding (Aug 14, 2026), +448.1% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
OTLK market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.52 | 0.53 | 0.49 | 0.49 | 3.09M |
| Oct 15, 2026 | 0.49 | 0.51 | 0.44 | 0.50 | 5.35M |
| Oct 14, 2026 | 0.56 | 0.56 | 0.47 | 0.47 | 9.64M |
| Oct 13, 2026 | 0.58 | 0.58 | 0.55 | 0.56 | 3.25M |
| Oct 12, 2026 | 0.60 | 0.60 | 0.57 | 0.58 | 2.31M |
| Oct 9, 2026 | 0.57 | 0.61 | 0.56 | 0.60 | 3.68M |
| Oct 8, 2026 | 0.58 | 0.59 | 0.55 | 0.56 | 4.00M |
| Oct 7, 2026 | 0.60 | 0.61 | 0.58 | 0.59 | 4.23M |
| Oct 6, 2026 | 0.60 | 0.62 | 0.57 | 0.57 | 3.16M |
| Oct 5, 2026 | 0.60 | 0.61 | 0.58 | 0.60 | 4.69M |
| Oct 2, 2026 | 0.59 | 0.61 | 0.57 | 0.59 | 5.62M |
| Oct 1, 2026 | 0.58 | 0.59 | 0.53 | 0.57 | 7.07M |
| Sep 30, 2026 | 0.63 | 0.63 | 0.57 | 0.57 | 9.01M |
| Sep 29, 2026 | 0.63 | 0.64 | 0.61 | 0.63 | 4.58M |
| Sep 28, 2026 | 0.63 | 0.64 | 0.60 | 0.62 | 6.10M |
| Sep 25, 2026 | 0.65 | 0.67 | 0.64 | 0.64 | 2.93M |
| Sep 24, 2026 | 0.66 | 0.68 | 0.64 | 0.66 | 2.78M |
| Sep 23, 2026 | 0.70 | 0.70 | 0.66 | 0.66 | 2.93M |
| Sep 22, 2026 | 0.69 | 0.71 | 0.68 | 0.70 | 2.85M |
| Sep 21, 2026 | 0.69 | 0.69 | 0.65 | 0.69 | 2.88M |
About Outlook Therapeutics
Outlook Therapeutics (OTLK) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in ISELIN, NJ. State of incorporation: DE. Fiscal year ends September 30. SEC CIK 1649989.
OTLK board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gerd Auffarth | Director | Oct 3, 2025 |
| Ventures & Investments Gms | Director | Aug 14, 2026 |
| Julian S Gangolli | Director | Oct 3, 2025 |
| Kurt J Hilzinger | Director | May 27, 2026 |
| Yezan Munther Haddadin | Director | Jun 3, 2026 |
| Julia A Haller | Director | Oct 3, 2025 |
| Andong Huang | Director | Oct 3, 2025 |
| Robert Charles Jahr | Chief Executive Officer | Aug 14, 2026 |
| Lawrence A Kenyon | Chief Financial Officer | Aug 14, 2026 |
| Faisal Ghiath Sukhtian | Director | Jul 29, 2026 |
| Ghiath M. Sukhtian | Director | Aug 14, 2026 |
| Randy H Thurman | Director | May 27, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert Charles Jahr | Chief Executive Officer | Aug 14, 2026 |
| Lawrence A Kenyon | Chief Financial Officer | Aug 14, 2026 |
| Kevin Michael Lundquist | Chief Financial Officer | Sep 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 14, 2026 | Lawrence A Kenyon | Buy | 101,010 | — |
| Aug 14, 2026 | Lawrence A Kenyon | Buy | 101,010 | — |
| Aug 14, 2026 | Lawrence A Kenyon | Buy | 101,010 | — |
| Aug 14, 2026 | Lawrence A Kenyon | Buy | 101,010 | — |
| Aug 14, 2026 | Robert Charles Jahr | Buy | 151,515 | — |
| Aug 14, 2026 | Robert Charles Jahr | Buy | 151,515 | — |
| Aug 14, 2026 | Robert Charles Jahr | Buy | 151,515 | — |
| Aug 14, 2026 | Robert Charles Jahr | Buy | 151,515 | — |
| Aug 12, 2026 | Ghiath M. Sukhtian | Buy | 2,525,252 | $0.99 |
| Aug 12, 2026 | Ghiath M. Sukhtian | Buy | 2,525,252 | $0.99 |
| Aug 12, 2026 | Ventures & Investments Gms | Buy | 2,525,252 | $0.99 |
| Aug 12, 2026 | Ventures & Investments Gms | Buy | 2,525,252 | $0.99 |
| Aug 12, 2026 | Ghiath M. Sukhtian | Buy | 2,525,252 | $0.99 |
| Aug 12, 2026 | Ghiath M. Sukhtian | Buy | 2,525,252 | $0.99 |
| Aug 12, 2026 | Ventures & Investments Gms | Buy | 2,525,252 | $0.99 |
OTLK financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Sep 30, 2025 | $1.41M | $-62.42M | -1.79 | $-51.83M |
| Sep 30, 2024 | — | $-75.37M | -4.06 | $-68.79M |
| Sep 30, 2023 | — | $-58.98M | -4.72 | $-42.97M |
| Sep 30, 2022 | — | $-66.05M | -0.31 | $-56.67M |
| Sep 30, 2021 | — | $-53.16M | -0.35 | $-54.25M |
Latest balance sheet: total assets $26.18M, total liabilities $36.58M, cash $11.24M (as of Jun 30, 2026).
OTLK earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | $0.76 |
| Aug 12, 2026 | 8-K Item 2.02 (results) | $1.10 |
| May 18, 2026 | 8-K Item 2.02 (results) | $0.23 |
| May 13, 2026 | 8-K Item 2.02 (results) | $0.23 |
| Feb 17, 2026 | 8-K Item 2.02 (results) | $0.42 |
| Dec 19, 2025 | 8-K Item 2.02 (results) | $2.01 |
| Aug 14, 2025 | 8-K Item 2.02 (results) | $2.43 |
| May 15, 2025 | 8-K Item 2.02 (results) | $1.67 |
| Feb 14, 2025 | 8-K Item 2.02 (results) | $1.87 |
| Dec 27, 2024 | 8-K Item 2.02 (results) | $2.01 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on OTLK
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.